The Transient Receptor Potential Cation Channel Subfamily V Member 1 pipeline drugs market research report outlays comprehensive information on the Transient Receptor Potential Cation Channel Subfamily V Member 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Transient Receptor Potential Cation Channel Subfamily V Member 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

The report also covers products from therapy areas such as Central Nervous System, Cardiovascular, Dermatology, and Genetic Disorders which include the indications Pain, Neuropathic Pain (Neuralgia), Cardiovascular Disease, Unspecified Cardiovascular Disorders, Pruritus, Chronic Urticaria Or Hives, Fragile X Syndrome, and Tuberous Sclerosis. It also reviews key players involved in Transient Receptor Potential Cation Channel Subfamily V Member 1 targeted therapeutics development with respective active and dormant or discontinued products.

The Transient Receptor Potential Cation Channel Subfamily V Member 1 pipeline targets constitutes close to 48 molecules. Out of which, approximately 41 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 5, 8, 2, 19, and 7 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 6, and 1 molecule.

Transient Receptor Potential Cation Channel Subfamily V Member 1 overview

The transient receptor potential cation channel subfamily V member 1 (TrpV1) is a protein encoded by the TRPV1 gene. It belongs to a sub-family of the transient receptor potential protein group. It mediates proton influx and may be involved in intracellular acidosis in nociceptive neurons. It is involved in mediation of inflammatory pain and hyperalgesia. It sensitized by a phosphatidylinositol second messenger system activated by receptor tyrosine kinases, which involves PKC isozymes and PCL. It is activated by endogenous compounds, including 12-hydroperoxytetraenoic acid and bradykinin. It acts as ionotropic endocannabinoid receptor with central neuromodulatory effects.

For a complete picture of Transient Receptor Potential Cation Channel Subfamily V Member 1’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.